CASP3 and melanoma: As we previously demonstrated in a similar experimental setting [16], in melanoma cells cisplatin treatment puts into motion the activation of conventional calpains, and two pharmacological inhibitors of these calpains (MDL-28170 and calpeptin), although not affecting the cytostatic effect of cisplatin, significantly protect from apoptotic cell death (Fig 2D and E), evaluated as cell detachment and caspase-3/-7 activity.